Insulin glargine U300, marketed as Toujeo, is a long-acting basal insulin used to manage blood sugar levels in adults and children with diabetes mellitus. It is a man-made form of insulin that is chemically identical to human insulin but has been modified to provide a longer duration of action.
How does Toujeo work?
Toujeo's extended duration of action is achieved through its formulation. The insulin glargine is formulated in a solution that allows for a slow and sustained release into the bloodstream. This provides a relatively constant basal insulin level for approximately 24 hours, helping to control fasting blood glucose levels [1].
What is the difference between Toujeo and other insulin glargine products?
Toujeo is a concentrated formulation of insulin glargine, containing 300 units per milliliter (U300). This is a higher concentration than some other insulin glargine products, such as Lantus (insulin glargine U100), which contains 100 units per milliliter. The higher concentration of Toujeo means that a smaller injection volume is needed to deliver the same dose of insulin, which can be beneficial for some patients [2].
When does Toujeo's patent expire?
The patent expiry for Toujeo (insulin glargine U300) is a complex issue that can be influenced by multiple patents covering different aspects of the drug, including its formulation, manufacturing process, and methods of use. Information on patent expiry dates can be found on specialized databases. For detailed patent information, DrugPatentWatch.com offers resources that track these expirations [3].
Who manufactures Toujeo?
Toujeo is manufactured by Sanofi, a global pharmaceutical company [1].
What are the clinical studies on Toujeo?
Clinical trials have evaluated Toujeo's efficacy and safety in various patient populations with type 1 and type 2 diabetes. Studies have shown that Toujeo effectively reduces HbA1c levels and fasting plasma glucose compared to placebo and other insulin treatments. Safety profiles are generally consistent with other long-acting insulins, with the most common side effect being hypoglycemia (low blood sugar) [1].
What are the potential side effects of Toujeo?
The most common side effect of Toujeo, like other insulins, is hypoglycemia. Other potential side effects include injection site reactions, lipodystrophy (changes in fat tissue at injection sites), and allergic reactions. Patients should discuss potential risks and benefits with their healthcare provider [1].
Can biosimilars of Toujeo be developed?
The development of biosimilars for biological drugs, including insulin products, is possible after patent expiry and the lapse of other market exclusivities. However, the process for biosimilar approval is rigorous and requires demonstrating similarity in terms of safety, efficacy, and quality. The availability of biosimilar versions of insulin glargine U300 would depend on regulatory approvals and market dynamics following patent expiries [3].